LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Avatud

1.27 -3.79

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.26

Max

1.32

Põhinäitajad
By Trading Economics
Sissetulek	2.7M -24M
Aktsiakasum	-0.354
Töötajad	171
EBITDA	-5.3M -28M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+108.59% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-615K 80M
Eelmine avamishind	5.06
Eelmine sulgemishind	1.27

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. märts 2026, 18:34 UTC

Tulu

Canada to Allow Smaller Companies to Ax Quarterly Earnings Reports in Pilot

19. märts 2026, 17:43 UTC

Suurimad hinnamuutused turgudel

Ecolab Dips on Report of Deal for CoolIT Systems With KKR

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings: Geopolitical Tensions Will Continue Driving Regional Fragmentation >1919.HK

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings: Container Shipping Market Saw Fluctuating, Declining Freight Rates >1919.HK

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings 2025 Rev CNY219.50B Vs. CNY233.86B >1919.HK

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings 2025 Net CNY30.86B Vs. Net CNY49.17B >1919.HK

19. märts 2026, 23:39 UTC

Tulu

Li Ning 2025 Net CNY2.94B Vs. Net CNY3.01B >2331.HK

19. märts 2026, 23:39 UTC

Tulu

Li Ning: Will Continue Targeting Consumer Needs, Strengthening User Engagement >2331.HK

19. märts 2026, 23:39 UTC

Tulu

Li Ning: Outdoor Category Continued Growing >2331.HK

19. märts 2026, 23:38 UTC

Tulu

Li Ning 2025 Rev CNY29.60B Vs. CNY28.68B >2331.HK

19. märts 2026, 23:33 UTC

Market Talk

Gold Edges Lower on Inflation Concerns, Dimmed Fed Rate-Cut Hopes -- Market Talk

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Unilever in Talks to Separate Food Business and Combine It With McCormick -- WSJ

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

McCormick Has a Market Value of Around $14.8B -- WSJ

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Unilever in Talks to Combine Food Business With McCormick, Sources Say -- WSJ

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

All-Stock Unilever-McCormick Deal Could Come Together Within Weeks, Sources Say -- WSJ

19. märts 2026, 22:23 UTC

Market Talk

FedEx Says It Can Raise Prices to Offset Higher Fuel Costs -- Market Talk

19. märts 2026, 22:09 UTC

Market Talk

Uudisväärsed sündmused

Australian Transport Stocks to Trade at Discount On Fuel Risks -- Market Talk

19. märts 2026, 22:06 UTC

Market Talk

Sigma Healthcare's New Bull Expects Profit Margins to Widen -- Market Talk

19. märts 2026, 22:04 UTC

Tulu

Omandamised, ülevõtmised, äriostud

FedEx CFO: MD-11 Grounding Led to $120M Headwind to Adjusted Operating Income in 3Q

19. märts 2026, 22:03 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

19. märts 2026, 22:03 UTC

Market Talk

Uudisväärsed sündmused

Fuel Prices, Scarcity Could Leave Mark on Australia's Gold Miners -- Market Talk

19. märts 2026, 21:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

FedEx CEO: InPost Deal Expected to Be Accretive to Earnings in Year One After Close

19. märts 2026, 20:57 UTC

Uudisväärsed sündmused

Middle East Attacks, Inflation Fears Weigh on Stocks -- WSJ

19. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

19. märts 2026, 20:19 UTC

Uudisväärsed sündmused

Brent Crude Retreats After Touching $119 -- WSJ

19. märts 2026, 19:49 UTC

Market Talk

Brent Crude Seen Potentially Rising to Top Its 2008 High -- Market Talk

19. märts 2026, 19:26 UTC

Uudisväärsed sündmused

U.S. Consumers Face 'Global Oil Shock.' The Iran War Is Retail's Latest Challenge. -- Barrons.com

19. märts 2026, 19:10 UTC

Market Talk

Uudisväärsed sündmused

Natural Gas Rises in Volatile Trading -- Market Talk

19. märts 2026, 19:06 UTC

Uudisväärsed sündmused

Brent Crude Prices Are Surging. Why Europe Is Facing an Energy Shock and the U.S. Isn't. -- Barrons.com

19. märts 2026, 18:08 UTC

Market Talk

Uudisväärsed sündmused

Silver Extends Slide to Seven Straight Sessions -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

108.59% tõus

12 kuu keskmine prognoos

Keskmine 2.67 USD 108.59%

Kõrge 3 USD

Madal 2 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.